Test ID FMPP Myocarditis/Pericarditis Panel
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CXB_1 | Coxsackie B(1-6) Antibodies, S | Yes, (Order COXB) | Yes |
ECH_1 | Echovirus Antibody Panel, Serum | Yes, (Order ECHO) | Yes |
FINFL | Influenza Types A and B Ab, Serum | No | Yes |
FCPAB | Chlamydophila pneumoniae Ab IgG/M/A | No | Yes |
Method Name
Complement Fixation (CF)/Immunoflourescence Assay (IFA)
Reporting Name
Myocarditis/Pericarditis PanelSpecimen Type
SerumContainer/Tube:
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 3 mL
Specimen Minimum Volume
2 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Refrigerated (preferred) | 14 days |
Frozen | 30 days | |
Ambient | 7 days |
Reference Values
MYOCARDITIS-PERICARDITIS PANEL
COXSACKIE B(1-6) ANTIBODIES, SERUM
REFERENCE RANGE: <1:8
INTERPRETIVE CRITERIA:
<1:8 Antibody Not Detected
≥ 1:8 Antibody Detected
Single titers of ≥ 1:32 are indicative of recent infection. Titers of 1:8 or 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.
This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.
ECHOVIRUS ANTIBODIES, SERUM
REFERENCE RANGE: <1:8
INTERPRETIVE CRITERIA:
<1:8 Antibody Not Detected
≥ 1:8 Antibody Detected
Single titers ≥ 1:32 are indicative of recent infection. Titers of 1:8 and 1:16 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis. There is considerable crossreactivity among enteroviruses; however, the highest titer is usually associated with the infecting serotype.
This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.
INFLUENZA TYPES A AND B ANTIBODIES, SERUM
REFERENCE RANGE: <1:8
INTERPRETIVE CRITERIA:
<1:8 Antibody Not Detected
≥ 1:8 Antibody Detected
Single titers of ≥ 1:64 are indicative of recent infection. Titers of 1:8 to 1:32 may be indicative of either past or recent infection, since CF antibody levels persist for only a few months. A four-fold or greater increase in titer between acute and convalescent specimens confirms the diagnosis.
This test was developed and its performance characteristics have been determined by Focus Diagnostics. Performance characteristics refer to the analytical performance of the test.
CHLAMYDOPHILA PNEUMONIAE ANTIBODIES (IgG,
IgA, IgM)
REFERENCE RANGE: IgG <1:64
IgA <1:16
IgM <1:10
The immunofluorescent detection of specific antibodies to Chlamydophila pneumoniae may be complicated by cross-reactive antibodies, non-specific antibody stimulation, or past exposure to similar organisms such as C. psittaci and Chlamydia trachomatis. IgM titers of 1:10 or greater usually indicate recent infection, and any IgG titer may indicate past exposure. IgA is typically present at low titers during primary infection, but may be elevated in recurrent exposures or in chronic infection.
These assays were developed and their performance characteristics have been determined by Focus Diagnostics. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.
Day(s) Performed
Varies; Monday through Saturday
Report Available
1 - 5 daysPerforming Laboratory
Focus Diagnositics, Inc.Test Classification
These assays were developed and their performance characteristics have been determined by Focus Diagnostics. They have not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. Performance characteristics refer to the analytical performance of the test.CPT Code Information
86658 x 11-Enterovirus
86710 x 2-Antibody; influenza virus
86331 x 2-Immunodiffusion
86632-Chlamydia, IgM